



Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

## Complete if Known

Application Number 09/516,728

Filing Date 03/01/2000

First Named Inventor T. O. Daniel et al.

Group Art Unit Not Assigned

Examiner Name Not Assigned

Attorney Docket Number 1242/12/2

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Honda et al., "Molecular Cloning, Characterization, and Chromosomal Localization of a Novel Protein-Tyrosine Phosphatase, HPTP", Blood, Vol. 84, (1994) pp. 4186-4194	
	C2	Borges et al., "Cloning and Characterization of Rat Density-Enhanced Phosphatase-1, a Protein Tyrosine Phosphatase Expressed by Vascular Cells", Circulation Research, Vol. 79, No. 3, (September 1996) pp. 570-580	
	C3	Keane et al., "The Protein Tyrosine Phosphatase DEP-1 is Induced During Differentiation and Inhibits Growth of Breast Cancer Cells", Cancer Research, Vol. 56, (September 15, 1996) pp. 4236-4243	
	C4	Ostman et al., "Expression of DEP-1, a Receptor-Like Protein-Tyrosine-Phosphatase, is Enhanced with Increasing Cell Density", Proc. Natl. Acad. Sci. USA, Vol. 91, (October 1994) pp. 9680-9684	

Examiner  
Signature

Date

Considered

2/17/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)  
App. for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/516,728
		Filing Date	03/01/2000
		First Named Inventor	Thomas O. Daniel
		Group Art Unit	1623-1642
		Examiner Name	ef. Bansa
		Attorney Docket Number	1242/12/2
Sheet	1	of	1



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB	C1	TAKAHASHI ET AL., "Glomerular Endothelial Localization of Receptor Tyrosine Phosphatase," Journal of the American Society of Nephrology, Vol. 9, p. 368A, (September, 1998). - Abstract only	X
	C2	PCT International Search Report for corresponding PCT application number PCT/US99/19965.	

RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

Examiner Signature		Date Considered	2/17/02
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Complete if Known**

<b>Application Number</b>	09/516,728
<b>Filing Date</b>	03/01/2000
<b>First Named Inventor</b>	Thomas O. Daniel
Group Art Unit	1642
<b>Examiner Name</b>	Bansal, G.
Attorney Docket Number	1242/12/2 PCT/US

(use as many sheets as necessary)

Sheet 1 of 1

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

217102

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box -

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	09/516,728
Filing Date	03/01/2000
First Named Inventor	Thomas O. Daniel
Group Art Unit	1642
Examiner Name	Bansal, G.
Attorney Docket Number	1242/12/2 PCT/US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	TAKAHASHI ET AL., "Endothelial Cell Receptor Tyrosine Phosphatase/Density Enhanced Phosphatase-1, ECRT/DEP-1, is an Oligomerization Responsive Angiostatic Switch," The FASEB Journal, Vol. 13 (No. 5), p. A694, (March 15, 1999).	X
	C2	DE LA FUENTE-GARCIA ET AL., "CD148 is a Membrane Protein Tyrosine Phosphatase Present in All Hematopoietic Lineages and is Involved in Signal Transduction on Lymphocytes," Blood, Vol. 91 (No. 8), p. 2800-2809, (April 15, 1998).	X
	C3	TANGYE ET AL., "CD148: a Receptor-Type Protein Tyrosine Phosphatase Involved in the Regulation of Human T Cell Activation," The Journal of Immunology, Vol. 161 (No. 7), p. 3249-3255, (October 1, 1998).	X
	C4	TAKAHASHI ET AL., "Endothelial Localization of Receptor Tyrosine Phosphatase, ECRT/DEP-1, Developing and Mature Renal Vasculature," The Journal of the American Society of Nephrology, Vol. 10 (No. 10), p. 2135-2145, (1999).	X
	C5	STOCKINGER ET AL., "New Human Leukocyte Clusters of Differentiation," Transfusion, Vol. 38 (No. 5), p. 499-505, (1998).	X

Examiner  
Signature

Date

Considered

2/17/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

